The use of recombinant human bone morphogenetic protein-2 (rhBMP-2) in orthopaedic applications.

摘要: Preclinical proof-of-concept, feasibility and efficacy studies in lower animals resulted the accumulation of data that served as a backbone for clinical trials with recombinant, osteogenic bone morphogenetic protein-2 (BMP-2). Among important observations was dependence dose carrier on outcome osseous union relation to animal model used. Clinical spinal applications indicate better overall results compared traditional controls utilised autogenous iliac crest graft fusion. Parameters include less blood loss, operating room time costs, fusion outcomes increased patient satisfaction. At this juncture, long journey from identification BMP-2 demineralised fraction FDA approval use singular orthopaedic application has been completed. It demonstrated be safe, efficacious cost-effective, leading satisfaction improved outcome.